原始来源记录
重大申请已提交
Inhibrx提交BLA申请ozekibart用于常规软骨肉瘤
Inhibrx于2026年4月向FDA提交了ozekibart用于常规软骨肉瘤的BLA申请。公司还计划在2026年下半年与FDA会面，讨论CRC一线注册试验以及ozekibart在CRC四线和难治性尤文肉瘤中的潜在加速审批途径。
关键事实
- 申报时间
- 2026年5月14日 20:04
- 事件
- 申请已提交
- 方向
- 中性
- 来源
- SEC 8-K
- 可信度
- 有来源
来源摘录
EX-99.1 2 exhibit99103312026.htm EX-99.1 Document Exhibit 99.1 Inhibrx Reports First Quarter 2026 Financial Results San Diego, CA, May 14, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the first quarter of 2026. The biopharmaceutical company has two programs in ongoing clinical trials. Recent Corporate Highlights and Upcoming Milestones • INBRX-106 ◦ In May 2026, we announced updated interim data from our randomized, first-line Phase 2 portion of the HexAgon study. The trial evaluated the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control arm) in first-line patients with treatment-naïve, PD-L1 positive (Combin